NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integer Holdings Corporation ("Integer Holdings Corporation" or the "Company") (NYSE: ITGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integer Holdings Corporation investors who were adversely affected by alleged securities fraud between July 25, 2024 and October 22, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during a specified period [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3][5]. Group 2: Allegations Against Integer Holdings Corporation - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and misrepresented its sales performance related to two of its EP devices [5]. - It is alleged that Integer's claims of strong visibility into customer demand were false, and the company mischaracterized its EP devices as a long-term growth driver for its cardio and vascular segment [5]. - The lawsuit asserts that the positive statements made by the defendants regarding Integer's business and prospects were materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been recognized for its performance in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [4].

NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integer Holdings Corporation ("Integer Holdings Corporation" or the "Company") (NYSE: ITGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integer Holdings Corporation investors who were adversely affected by alleged securities fraud between July 25, 2024 and October 22, 2025. Follow the link below to get more information and be contacted by a member of our team: http ...

Philadelphia, Pennsylvania--(Newsfile Corp. - January 5, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no l ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Integer Holdings Corporation designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company has been accused of overstating demand for its electrophysiology devices while publicly claiming strong sales growth [4][5]. Group 3: Stock Performance and Financial Guidance - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower adoption than anticipated [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as growth drivers [5]. - It is claimed that Integer experienced a deterioration in sales for two of its EP devices, contradicting its public statements about strong customer demand [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

LOS ANGELES, Jan. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. Inte ...

Core Viewpoint - A class action has been initiated against Integer Holdings Corporation, alleging that the company made false statements regarding its competitive position and sales performance in the electrophysiology manufacturing market during the specified class period from July 25, 2024, to October 22, 2025 [1][3]. Group 1: Legal Action - The Portnoy Law Firm is representing investors who purchased securities during the class period and encourages them to file a lead plaintiff motion by February 9, 2026 [1]. - Investors can contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss options for recovering losses [2]. Group 2: Allegations Against the Company - The complaint alleges that Integer materially overstated its competitive position within the electrophysiology manufacturing market [3]. - It is claimed that despite Integer's assertions of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - The company mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about its business and prospects [3].